PP
HRMY icon

Paloma Partners’s Harmony Biosciences HRMY Stock Holding History

Paloma Partners’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,617
Closed -$936K – 95
2025
Q2 		$936K Buy
+29,617
New +$953K 0.14% 78

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
VM
Valor Management Chicago, Illinois $86.2B AUM 12.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paloma Partners's HRMY Position: Q3 2025 in Review

Paloma Partners sold out of Harmony Biosciences (HRMY) in Q3 2025, closing a stake of 29,617 shares — an estimated $936K sold.

Paloma Partners first reported a position in HRMY in Q2 2025 and held it in 1 quarter. The position peaked at $936K in Q2 2025. 296 funds tracked by Wall St. Rank hold HRMY as of Q3 2025.

  • Paloma Partners reported no remaining Harmony Biosciences position as of Q3 2025 after selling out during the quarter.
  • Paloma Partners sold 29,617 Harmony Biosciences shares in Q3 2025, an estimated $936K.
  • Paloma Partners first reported a position in Harmony Biosciences in Q2 2025 and held it in 1 quarter.
  • Paloma Partners's Harmony Biosciences position peaked at $936K in Q2 2025.
  • 296 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2025.

Based on Paloma Partners's 13F filing for Q3 2025, filed 14 Nov 2025.